Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
Cullinan Therapeutics, a biopharmaceutical company focused on developing targeted therapies, has announced that its CEO, Nadim Ahmed, and CMO, Jeffrey Jones, will participate in a fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit.
The event, which will take place virtually on May 28 and 29, 2024, will feature their chat on May 29 at 11:30 am ET. A webcast of the event will be accessible on the company's investor relations website.
- Participation in a high-profile event like the TD Cowen 5th Annual Oncology Innovation Summit increases exposure and credibility for Cullinan Therapeutics.
- The involvement of top executives, CEO Nadim Ahmed and CMO Jeffrey Jones, suggests a commitment to transparency and leadership engagement.
- The press release does not mention any immediate financial or clinical milestones, which might be a concern for investors looking for tangible progress.
- There is no new data or clinical results being presented, which might be seen as a lack of substantial news or advancements.
CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer and Jeffrey Jones, MD, MBA, Chief Medical Officer, will participate in a fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, being held virtually on May 28 and 29, 2024.
The fireside chat is scheduled for Wednesday, May 29, 2024 at 11:30am Eastern Time. A webcast will be available under the Events and Presentations section of the Company’s investor relations website at https://cullinantherapeutics.com/events-and-presentations/.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. We have strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Our portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of cancer and autoimmune indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about our Company at https://cullinantherapeutics.com/, and follow us on LinkedIn and X.
Contacts:
Investor Relations
Chad Messer
+1 203.464.8900
cmesser@cullinantx.com
Media
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com
FAQ
What event is Cullinan Therapeutics participating in?
When is the fireside chat with Cullinan Therapeutics scheduled?
Who will represent Cullinan Therapeutics at the Oncology Innovation Summit?
Where can I watch the webcast of the Cullinan Therapeutics fireside chat?
What is the focus of Cullinan Therapeutics?
